D. E. Shaw & Co., Inc. Aquestive Therapeutics, Inc. Transaction History
D. E. Shaw & Co., Inc.
- $107 Billion
- Q3 2024
A detailed history of D. E. Shaw & Co., Inc. transactions in Aquestive Therapeutics, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 31,046 shares of AQST stock, worth $111,144. This represents 0.0% of its overall portfolio holdings.
Number of Shares
31,046Holding current value
$111,144% of portfolio
0.0%Shares
10 transactions
Others Institutions Holding AQST
# of Institutions
122Shares Held
46.8MCall Options Held
517KPut Options Held
207K-
Bratton Capital Management, L.P. Fort Worth, TX9.81MShares$35.1 Million100.0% of portfolio
-
Vr Adviser, LLC New York, NY5.56MShares$19.9 Million2.87% of portfolio
-
Black Rock Inc. New York, NY5.45MShares$19.5 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.26MShares$15.3 Million0.0% of portfolio
-
Franklin Resources Inc San Mateo, CA2.77MShares$9.9 Million0.0% of portfolio
About Aquestive Therapeutics, Inc.
- Ticker AQST
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,350,700
- Market Cap $191M
- Description
- Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual f...